Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand
Characterisation of pncA mutations in clinical Mycobacterium tuberculosis isolates in New Zealand
复制标题
DOI：
10.1080/00313020903071587
复制
发表时间：
2009-01-01
期刊：
影响因子：
4.5
通讯作者：
Drinkovic, Dragana
中科院分区：
文献类型：
--
作者：
Pandey, Sushil;Newton, Sandie;Drinkovic, Dragana
目的：目的探讨新西兰结核分枝杆菌对吡嗪酰胺（PZA）耐药的分子基础，并比较新西兰结核分枝杆菌PZA耐药表型（Bactec 960和韦恩氏试验）菌株的pncA基因序列。对通过表型方法发现为PZA抗性的结核病进行测序。结果：在11株耐药菌株中检测到突变，主要发生在多重耐药表型菌株中。虽然这些突变沿着pncA基因分散，但在氨基酸Ser 18-His 57和His 82-Val 128区域发现了突变簇。结论：PZA耐药株中pncA基因突变具有高度的多样性。结核Bactec 960表型试验可能过度报告PZA耐药性。
Aims: To describe the molecular basis of pyrazinamide (PZA) resistance among Mycobacterium tuberculosis in New Zealand, and to compare the pncA gene sequence among isolates with phenotypic (Bactec 960 and Wayne's assay) evidence of PZA resistance.Methods: The pncA gene of 26 clinical isolates of M. tuberculosis found to be PZA resistant by phenotypic methods was sequenced. Phenotypic and genotypic data were compared.Results: Mutations were detected in 11 isolates, predominantely among isolates with a multi-drug resistance phenotype. While the mutations were dispersed along the pncA gene, a clustering of mutations were found at amino acid Ser18-His57 and His82-Val128 regions. Seven of the identified mutations have not been described previously.Conclusions: A high diversity of pncA gene mutation was seen among PZA resistant strains of M. tuberculosis. The Bactec 960 phenotypic test may over report PZA resistance.